Navigating the DSCSA ATP Requirement: Manual vs. Automated Compliance for Pharma
Article summary: This article explains the US Drug Supply Chain Security Act's Authorized Trading Partner verification requirement and why, in 2026, it has become one of the highest-risk compliance gaps for US pharma. It's written for manufacturers, repackagers, wholesale distributors, 3PLs, and dispensers who must verify every trading partner's authorization status before doing business with them. The stakes span three areas: regulatory exposure (FDA Warning Letters and Form 483 citations), commercial exposure (PBM audits, chargebacks, and network termination), and operational efficiency (automated, interoperable checks vs. manual spreadsheets). With FDA's stabilization period over and dispenser exemptions expiring through November 2026, this piece walks through how to decide between manual and automated ATP verification, what each pathway requires, and closes with a practical readiness checklist.
What Is the DSCSA Authorized Trading Partner (ATP) Requirement?
The Drug Supply Chain Security Act (DSCSA) requires every entity in the US pharmaceutical supply chain (manufacturers, repackagers, wholesale distributors, and dispensers) to engage only with other "Authorized Trading Partners," also known as ATP. An ATP is a trading partner that holds a valid, state license or FDA registration appropriate to its role, and isn't otherwise excluded (for example, under an FDA import alert or state licensing action). Before any transaction, each party should verify the other's authorization status and be able to produce evidence of that check. The obligation to only transact with ATPs applies regardless of company size, and it doesn't lapse once serialization or tracing systems are in place; it's an ongoing, per-relationship duty, as Spherity's overview of the foundational ATP requirement lays out.
Why Is FDA Enforcing ATP Verification So Aggressively Now?
The era of "educational enforcement" under DSCSA is over. FDA's one-year stabilization period ran through November 27, 2024, and phased exemptions have since expired for manufacturers and repackagers (May 27, 2025) and wholesale distributors (August 27, 2025); large dispensers lost their exemption on November 27, 2025, with only eligible small dispensers covered through November 27, 2026, as ArentFox Schiff and Spherity's own analysis of the shift from deadlines to Warning Letters both detail.
The enforcement record backs this up. In June 2025, FDA sent a Warning Letter to Sterling Distributors citing, among other findings, that the firm "could not demonstrate that it took any action to verify the licensure or reporting status of its direct trading partner," and that it had "no systems in place" addressing DSCSA verification requirements at all. Then, in a case that ArentFox Schiff flagged as a turning point, FDA issued its first DSCSA Form 483 to a dispenser: a Texas med spa, Pure Indulgence Aesthetics, after comparing FDA-obtained Botox purchase records from AbbVie and its subsidiary Allergan Aesthetics against the dispenser's own patient treatment records, finding that dispensed units significantly exceeded what had been legitimately purchased through authorized channels. Sterling couldn't produce evidence it had checked its trading partner's status; Pure Indulgence couldn't account for where the excess product came from. If an inspector asks for that proof and you don't have it, you are already in violation, since the transaction itself is illegal under DSCSA, independent of any other issue with the product.
How Are PBMs Enforcing DSCSA Compliance Separately From the FDA?
Pharmacy Benefit Managers have become a second, and often faster-moving, enforcement layer. For example, PBMs used to request DSCSA “T3" documentation (Transaction Information, Transaction History, and Transaction Statements) as part of routine and for-cause pharmacy audits. Any other DSCSA requirement may also be checked by them. A pharmacy that can't produce evidence requested by PBMs can face claim chargebacks, inventory-discrepancy findings, and in unresolved cases, termination from the PBM's network entirely. Unlike an FDA inspection, a PBM audit isn't announced years in advance and carries immediate commercial consequences: lost reimbursement and lost network access, not a future warning letter. Pharmacies that treat ATP verification as purely an FDA-facing exercise are underestimating where the near-term financial pain is actually most likely to come from.
Can Automating ATP Checks Improve Business Efficiency, Not Just Compliance?
Yes, and this is the part of the requirement most organizations underuse. Verifying licenses doesn't have to slow transactions down. Interoperable ATP credentials specified by the Open Credentialing Initiative (OCI) let trading partners exchange proof of authorization through digital wallets in near-real time, embedded directly in existing verification and tracing messages. Instead of a person manually checking a state board website, the credential check happens automatically as part of the transaction. Paired with real-time license data feeding your master data systems (rather than a static, manually updated spreadsheet), this reduces onboarding friction for new partners, cuts human error, and gives you a defensible, timestamped audit trail without adding staff hours.
How Often Should You Check a Trading Partner's ATP Status?
Frequency is the critical decision. Checking monthly means a partner's license could be suspended on day two, leaving up to 28 days of non-compliant transactions before you catch it. Weekly checks narrow but don't close that gap. Only verifying at the point of each business interaction, whether per transaction, per shipment, or per new relationship, closes the exposure window completely. Real-time, per-interaction verification is where the industry is heading, and increasingly what an inspector or PBM auditor will expect to see.
Manual vs. Automated ATP Verification: Which Pathway Fits Your Organization?
Once you've set your frequency target, you need an execution model. Both pathways can technically satisfy DSCSA, but they carry very different long-term risk profiles.
The manual pathway, checking each of the roughly 50 state licensing board portals by hand and saving PDF screenshots as evidence, looks cheaper upfront, but it often saves money at the wrong end of the process. It requires staff trained to navigate inconsistent state portals and interpret what counts as a "valid" status; it's vulnerable to simple human error, like an overlooked expiration date or a mistyped license number; it stalls the moment the one employee who owns the "compliance spreadsheet" goes on leave or leaves the company; and it can't dynamically adapt as state and federal interpretations of DSCSA continue to evolve.
The automated pathway replaces that fragility with software. Dispensers and distributors can integrate third-party license and ATP verification tools, including solutions powered by Spherity, directly into their operational workflow, so licenses across state boards and federal registries are tracked, pinged, and verified continuously rather than on a manual cadence. Manufacturers, wholesalers, and 3PLs handling product verifications (including saleable returns) should look for a Verification Router Service that includes OCI-compliant ATP credentials as a built-in part of the package, so every verification request is credential-checked automatically at the moment it's sent or received. Organizations that want to go further extend ATP verification into their broader master data management (MDM) architecture, so a vendor with an expired or flagged credential simply can't be issued a purchase order in the first place: compliance enforced structurally, not procedurally.
What Is the Open Credentialing Initiative, and How Do ATP Credentials Work?
Open Credentialing Initiative (OCI) is the nonprofit, cross-industry group, formed in April 2021 out of an earlier pilot with the Center for Supply Chain Studies, major manufacturers, and distributors, that defines the open technical specification for interoperable ATP credentials, as OCI's own overview and Pharmaceutical Commerce's reporting describe. Under the OCI model, a Credential Service Provider verifies a trading partner's identity and license status at onboarding, then issues digital identity and ATP credentials into that partner's digital wallet. From then on, the established ATP status is continuously monitored and other trading partners' systems can check those credentials automatically, without a prior direct relationship and without needing any technical expertise on either side. The design goal is interoperability: any OCI-conformant service provider should be able to verify a credential issued by any other, using shared GS1, W3C, and NIST-based standards, fast enough to keep pace with the roughly 60,000 active trading partners in the US life sciences supply chain and the sub-24-hour (often sub-one-minute) verification windows DSCSA workflows require.
What Role Does a Verification Router Service (VRS) Play?
The Verification Router Service (VRS) was originally mainly designed as the industry-standard infrastructure for the DSCSA Saleable Returns requirement, which obligates wholesale distributors to verify a product identifier on each returned unit before reselling it, with manufacturers required to respond to verification requests within 24 hours, per HDA's VRS Guidance and FAQ documentation. Since then, its scope has widened, with even regulators using the software for inspections. An example is Louisiana's Board of Drug and Device Distributors, which also uses its own OCI-specified DSCSA Authority credential and has been educating industry stakeholders through public exercises. HDA's guidance is explicit that "neither a DEA license nor the FDA website" alone counts as sufficient documentation of a distributor's authorization. This is exactly the gap OCI-specified ATP credentials are designed to close: a growing number of VRS platforms now embed OCI credential checks directly into the verification flow, so product-identifier verification and trading-partner-authorization verification happen as a single automated step rather than two separate manual processes.
How Long Must ATP Verification Records Be Retained?
DSCSA requires transaction information, transaction statements, and your ATP verification records to be retained for at least six years under §582(c)(1)(C), longer if a suspect or illegitimate product investigation is involved, since FDA guidance then requires those records for six years past the investigation's conclusion, pushing total potential retention toward twelve years. In practice, your evidence-collection method (screenshots, credential logs, audit trails) needs to be durable, searchable, and producible within regulatory timeframes, typically one business day for most requests and 48 hours for dispensers, not just filed away and forgotten.
The DSCSA ATP Compliance Checklist
Use this list to assess how prepared your organization is:
Define your execution strategy: decide whether ATP verification will run on manual processes, automated software, or a hybrid, based on transaction volume and risk tolerance.
Establish check frequency: move toward per-transaction/per-interaction verification, or at minimum define a tight, documented risk-mitigation window if real-time isn't yet feasible.
Evaluate third-party providers: shop serialization solutions, VRS platforms, and dedicated license-verification tools that offer built-in OCI-specified, interoperable ATP credentials.
Audit your master data systems: confirm your MDM architecture has a live mechanism for real-time license and credential status updates, not static, manually refreshed fields.
Build evidence-collection SOPs: document exactly how each ATP check is logged and stored, retrievable within regulatory timeframes and retained for six years.
Formulate an absence-cover plan (if manual): assign a documented backup workflow for when the person who manages compliance checks is out.
Create staff training modules (if manual): establish recurring training on navigating state licensing boards and recognizing red flags or anomalies.
More About Spherity's Role in DSCSA Compliance Automation
Spherity Inc. is a global pioneer in digital identity software, helping enterprises create secure identity integrations for organizations, machines, products, data, and algorithms. Leveraging self-sovereign identity and verifiable credentials, Spherity streamlines compliance with data protection and security regulations. For DSCSA, Spherity offers CARO, a Drummond-certified ATP credentialing and master data solution, recently expanded from a VRS-integrated verification tool into a full ATP master data and communication hub. CARO automates identity and license verification, supports golden master data records, and integrates ATP credentials with VRS, tracing, ERP, and compliance systems. Spherity's ATP credentialing solution for DSCSA compliance won the HDA Distribution Management Award for strengthening the security of the US pharmaceutical supply chain. As FDA enforcement moves from stabilization to accountability, Spherity helps manufacturers, repackagers, wholesalers, 3PLs, dispensers, and solution providers prove that they are authorized, connected, and trusted.
Prepare before the next inspection, trading partner request, or DSCSA deadline. Schedule time with the CARO team to see how automated ATP checks, license verification, VRS-ready credentials, and audit-ready DSCSA master data can work for your organization.
